Data News > Cardlytics, Inc. Under Investigation for Securities Fraud Allegations
- Levi & Korsinsky, Pomerantz LLP, Hagens Berman, and The Schall Law Firm are all conducting investigations into Cardlytics, Inc.
- Cardlytics announced a decrease in revenue and adjusted contribution in its second quarter 2024 financial results.
- Karim Temsamani stepped down as CEO and from the Board of Directors of Cardlytics.
- Investors who suffered losses are urged to contact the law firms conducting the investigations.
- The investigations focus on potential violations of federal securities laws by Cardlytics.
Levi & Korsinsky, Pomerantz LLP, Hagens Berman, and The Schall Law Firm have all initiated investigations into Cardlytics, Inc., regarding possible violations of federal securities laws. The scrutiny follows Cardlytics' second quarter 2024 financial results announced on August 7, 2024, which disclosed a 9% year-over-year decrease in revenue to $69.6 million and a 3% decline in adjusted contribution to $36.4 million. Additionally, the company revealed that Karim Temsamani had resigned as Chief Executive Officer and from the Board of Directors.
Pomerantz LLP specifically advises investors of Cardlytics, Inc., to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. for more information regarding the investigation. Hagens Berman encourages individuals who may have insights to assist in the inquiry to reach out to their attorneys. The Schall Law Firm is requesting the public's participation in a securities fraud investigation into Cardlytics Inc., focusing on potential violations of securities laws by the company.
Investors who have suffered significant losses as a result of Cardlytics' financial results or actions are reminded to contact the respective law firms handling the investigations for further details. The ongoing inquiries aim to determine whether Cardlytics issued misleading statements or failed to disclose information that could have been important to investors. The investigations underscore the importance of transparency and accuracy in financial reporting to maintain investor trust and regulatory compliance.
For more information:
Up/Down Rally Price Distribution Analyst Recommendations Earning Price Impact Analysis Seasonality
Cardlytics, Inc. Under Investigation for Securities Fraud Allegations
By KlickAnalytics Data Insights | September 5, 2024 08:08PM ET
Key Points
- Levi & Korsinsky, Pomerantz LLP, Hagens Berman, and The Schall Law Firm are all conducting investigations into Cardlytics, Inc.
- Cardlytics announced a decrease in revenue and adjusted contribution in its second quarter 2024 financial results.
- Karim Temsamani stepped down as CEO and from the Board of Directors of Cardlytics.
- Investors who suffered losses are urged to contact the law firms conducting the investigations.
- The investigations focus on potential violations of federal securities laws by Cardlytics.
Levi & Korsinsky, Pomerantz LLP, Hagens Berman, and The Schall Law Firm have all initiated investigations into Cardlytics, Inc., regarding possible violations of federal securities laws. The scrutiny follows Cardlytics' second quarter 2024 financial results announced on August 7, 2024, which disclosed a 9% year-over-year decrease in revenue to $69.6 million and a 3% decline in adjusted contribution to $36.4 million. Additionally, the company revealed that Karim Temsamani had resigned as Chief Executive Officer and from the Board of Directors.
Pomerantz LLP specifically advises investors of Cardlytics, Inc., to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. for more information regarding the investigation. Hagens Berman encourages individuals who may have insights to assist in the inquiry to reach out to their attorneys. The Schall Law Firm is requesting the public's participation in a securities fraud investigation into Cardlytics Inc., focusing on potential violations of securities laws by the company.
Investors who have suffered significant losses as a result of Cardlytics' financial results or actions are reminded to contact the respective law firms handling the investigations for further details. The ongoing inquiries aim to determine whether Cardlytics issued misleading statements or failed to disclose information that could have been important to investors. The investigations underscore the importance of transparency and accuracy in financial reporting to maintain investor trust and regulatory compliance.
For more information:
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.